Tag: LBT

LBT Innovations ASX Beckman Coulter clinical diagnostic APAS

LBT Innovations signs Beckman Coulter to market APAS Independence throughout Europe

Australian medical technology company LBT Innovations (ASX: LBT) has signed a marketing agreement with clinical diagnostics specialist Beckman Coulter for the sale of its culture-plate screening and i...
LBT Innovations ASX APAS EU CE Mark Labor Dr Wisplinghoff

LBT Innovations makes first APAS sale in EU to Germany’s largest clinical laboratory

Australian medical technology company LBT Innovations (ASX: LBT) has announced the first sale of its APAS (Automatic Plate Assessment System) Independence instrument within the European Union, to Germ...
LBT Innovations ASX APAS Independence CE Mark MRSA clinical study

LBT Innovations receives green light for EU market entry, completes MRSA clinical study

Medical technology company LBT Innovations (ASX: LBT) is set to take its artificial intelligence-inspired APAS Independence instrument to Europe after obtaining the highly prized CE Mark certification...
LBT Innovations ASX APAS Invependence US FDA 510k clearance Clever Culture Systems

LBT Innovations receives FDA clearance to commercialise pathology screening device in US market

Australian medical technology company LBT Innovations (ASX: LBT) has received pre-market 510(k) clearance from the US Food and Drug Administration for its APAS (Automated Plate Assessment System) Inde...
LBT Innovations first sale APAS Independence Automated Plate Assessment System hospital

LBT Innovations completes first sale of APAS Independence

LBT Innovations (ASX: LBT) has announced the first sale of the company’s Automated Plate Assessment System (APAS) Independence instrument to a major hospital. Earlier today, the medical technology ...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS